Status: Recruiting
Trastuzumab Emtansine(T-DM1) After Trastuzumab Deruxtecan(T-DXd) in HER2-Positive Breast Cancer in Korea
Prospective observational study of trastuzumab emtansine immediately after trastuzumab deruxtecan in patients with advanced HER2-positive breast cancer in Korea
Participants needed: 100
Trial details
Age: 19+Biological sex: AllType: ObservationalSponsor: Seoul National University HospitalUpdated: Apr 23, 2026Locations: 1
Eligibility criteria
HER2-positive, advanced (unresectable locally advanced or metastatic) breast can... [+2]
Any systemic treatment, other than T-DM1, for breast cancer after trastuzumab de... [+3]